Invest-CTO PCI Trial

Launched by HAUKELAND UNIVERSITY HOSPITAL · Feb 24, 2021

Keywords

ClinConnect Summary

The Invest-CTO PCI Trial is studying a new approach to treat a condition called Chronic Total Occlusion (CTO) of the coronary artery, which can cause chest pain (angina) and affect quality of life. Sometimes, doctors perform procedures to help open blocked arteries, but they want to see if a planned two-step approach can make these procedures safer and more successful. The researchers believe that this strategy could lead to better health outcomes and a more positive experience for patients undergoing treatment.

To take part in this trial, participants need to be between the ages of 65 and 74, able to give written consent, and have a high-risk CTO that meets specific medical guidelines. Those who are pregnant, have certain types of blockages, or face other health risks might not be eligible. If accepted into the study, participants can expect to follow a scheduled treatment plan and receive careful monitoring. This trial aims to improve not just the success of the procedures but also the overall experience for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to provide written informed consent
• • Comply with the procedural and study follow-up schedule
• • Planned CTO PCI in accordance with the European and American appropriateness criteria.
• • CTO defined as high-risk
• Exclusion Criteria:
• • Non-high risk CTO
• • Occlusion within a stent
• • Flush aorto-ostial occlusion of RCA and Left Main (LMS)
• • Limited arterial access precluding repeat procedure
• • Baseline non invasive testing showing non-viable target vessel territory
• • Contra-indication to dual antiplatelet therapy
• • Pregnancy
• • Prior radiation skin injury
• • Lack of informed consent